Evaluation of the Clinical Benefit of a Transmitter for Contralateral Routing of Signals (CROS)

April 8, 2022 updated by: Sonova AG
This study will evaluate the clinical benefit of a transmitter for contralateral routing of signals. The benefit will be evaluated in noisy environments regarding speech intelligibility when the CROS system is adjusted to different microphone settings. Additionally, data regarding overall system stability, crash reboot rate, sound quality and connectivity will be obtained over a period of time to validate the CROS system in combination with smartphone and accessories. This study is a confirmatory study.

Study Overview

Detailed Description

Unilateral Hearing Loss (UHL) can be defined as any degree of permanent hearing loss on one ear with normal hearing in the opposite ear. Unilateral hearing loss can be debilitating associated with audiological, psychosocial and educational challenges. Audiological challenges include the reduced ability to localize sounds, reduced awareness on the unaidable side and difficulties hearing in noise or at a distance.

One solution for unaidable UHL is Contralateral Routing of Signals (CROS) and Bilateral Contralateral routing of signals (BiCROS) using a so- called CROS transmitter together with a hearing aid.

The rationale for this clinical investigation is to collect clinical data with a rechargeable CROS transmitter to evaluate the benefits of a BiCROS fitting compared to the alternative treatment option, the monaural hearing aid fitting, and to no treatment in noisy listening situations.

Study Type

Interventional

Enrollment (Actual)

23

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Zürich
      • Stäfa, Zürich, Switzerland, 8712
        • Sonova AG

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • hearing impaired adults, with & w/o hearing aids (experiences)
  • good written and spoken (Swiss) German language skills
  • ability to fill in a questionnaire conscientiously
  • informed consent as documented by signature
  • asymmetric hearing loss: one unaidable ear (min. N6 hearing loss) / the other ear with N3 or N4 hearing loss
  • availability of Smartphone
  • availability of TV or Tablet
  • ability to operate and handle the investigational device
  • ability to describe listening impressions/experiences and the use of the hearing aid
  • Ability to produce a reliable hearing test result

Exclusion Criteria:

  • Contraindications to the medical device:
  • aidable hearing loss on the intended CROS side
  • acute tinnitus (in either one ear and occurrence less than three months)
  • anatomical deformity of the CROS ear (e.g. absence of the auricle)
  • Known hypersensitivity or allergy to materials of the investigational device
  • any auricle deformities, that prevents secure placement of the (test) devices
  • no willingness to test the investigational device system
  • no willingness to test the investigational device system for at least 8h a day
  • Hint for psychological problems from investigators point of view
  • reported fluctuating hearing that could influence the test result
  • reported symptoms of vertigo and dizziness by participants

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Speech Intelligibility with CROS device

The focus of this study is on Speech Intelligibility (SI), evaluated by the Oldenburg Sentence test (OLSA), which measures a speech recognition threshold (SRT) in dB SNR (signal to noise ratio).

Therefore each participant will perform the tests with the experimental rechargeable CROS transmitter (CROS) in different interventions, like comparison to monaural fitting and unaided condition.

All participants will perform the same tests. The order of the intervention in the speech test is randomized, but will be performed in the same visit by each participant.

No treatment, i.e. the participants are not fitted with a CROS device and/ or hearing aid.

Unaided condition acts as control intervention.

Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible hearing device on the other ear.

Each participant will be fitted with a hearing aid on the better hearing ear and no device on the poorer, unaidable ear.

Monaural hearing aid fitting acts as control intervention.

Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible device on the other ear. The difference to the BiCROS condition is the setup of the microphones in the CROS device and the compatible hearing device.

This test condition is only tested for speech intelligibility in diffuse noise and acts as control intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Speech Intelligibility (SI) in noise (fix direction): BiCROS fitting vs. monaural hearing aid fitting
Time Frame: 2 weeks

The primary objective of this clinical investigation is to evaluate whether a BiCROS fitting (better ear fitted with a hearing device, unaidable ear supplied with a CROS device) improves speech intelligibility in noise compared to a monaural fitting (just the aidable ear is supplied by a hearing aid), for adults with an asymmetric hearing loss, measured with the Oldenburg Sentence Test (OLSA). Results of the speech test will be the SRT (speech recognition threshold) in dB SNR (signal to noise ratio).

The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SI in noise (fix direction): BiCROS fitting vs. unaided
Time Frame: 2 week

A secondary objective of this clinical investigation is to evaluate whether a BiCROS fitting improves speech intelligibility in noise compared to an unaided condition, for adults with an asymmetric hearing loss, measured with the Oldenburg Sentence Test (OLSA).

Results of the speech test will be the SRT (dB SNR). The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 week
SI in diffuse noise: BiCROS fitting vs. monaural fitting
Time Frame: 2 weeks

A secondary objective of this clinical investigation is to evaluate whether a BiCROS fitting improves speech intelligibility by at least 1 dB SNR for 50% SRT in diffuse noise, compared to a monaural hearing aid fitting.

The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks
SI in diffuse noise: BiCROS fitting vs. unaided
Time Frame: 2 weeks

A secondary objective of this clinical investigation is to evaluate whether a BiCROS fitting improves speech intelligibility by at least 1 dB SNR for 50% SRT in diffuse noise, compared to an unaided condition.

The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks
SI in diffuse noise: BiCROS vs. CROS baseline fitting
Time Frame: 2 weeks

A secondary objective of this clinical investigation is to evaluate whether a BiCROS fitting improves speech intelligibility in diffuse noise compared with a CROS baseline fitting. CROS baseline means a fitting of an additional program with different hearing instrument microphone setup.

The SI will be tested with the OLSA in diffuse noise. The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks
SI in diffuse noise: CROS baseline fitting vs. unaided
Time Frame: 2 weeks

A secondary objective of this clinical investigation is to evaluate whether a CROS baseline fitting improves speech intelligibility in diffuse noise compared with an unaided condition.

The SI will be tested with the OLSA in diffuse noise. The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks
SI in diffuse noise: CROS baseline fitting vs. monaural fitting
Time Frame: 2 weeks

A secondary objective of this clinical investigation is to evaluate whether a CROS baseline fitting improves speech intelligibility in diffuse noise compared with a monaural fitting.

The SI will be tested with the OLSA in diffuse noise. The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks
SP in diffuse noise: monaural fitting vs. unaided
Time Frame: 2 weeks

A secondary objective of this clinical investigation is to evaluate whether a monaural fitting improves speech intelligibility in diffuse noise compared with an unaided condition.

The SI will be tested with the OLSA in diffuse noise. The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks
Evaluation of Sound quality
Time Frame: 3 weeks

A secondary objective of this study is to evaluate the participant's satisfaction of the sound quality of the experimental CROS device by a subjective rating during a three-week home trial period.

Scale: very unsatisfied- unsatisfied- neither nor- satisfied- very satisfied

3 weeks
Evaluation of System stability
Time Frame: 3 weeks

A secondary objective of this study is to evaluate the participant's satisfaction of the system stability of the experimental CROS device during a three-week home trial period.

The participant shall report, if there are artefacts audible: never/ 1-2 times a week/ 3-6 times a week/ daily

3 weeks
Evaluation of streaming
Time Frame: 3 weeks

A secondary objective of this study is to evaluate the participant's satisfaction of the streaming sound quality of the experimental CROS device, by a subjective rating during a three-week home trial period.

Scale: very unsatisfied- unsatisfied- neither nor- satisfied- very satisfied

3 weeks
Evaluation of listening effort
Time Frame: 3 weeks

A secondary objective is to evaluate the subjective listening effort in noise reported by the participant whilst wearing the experimental CROS device.

Scale: not at all - slightly - somewhat - moderately - very - extremely

3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 26, 2021

Primary Completion (Actual)

March 14, 2022

Study Completion (Actual)

March 14, 2022

Study Registration Dates

First Submitted

October 22, 2021

First Submitted That Met QC Criteria

October 22, 2021

First Posted (Actual)

November 3, 2021

Study Record Updates

Last Update Posted (Actual)

April 15, 2022

Last Update Submitted That Met QC Criteria

April 8, 2022

Last Verified

November 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hearing Loss

Clinical Trials on Unaided condition

Subscribe